Skip to main content

Advertisement

Table 1 Drug-induced changes in short circuit current (SCC)

From: Combined activity of COX-1 and COX-2 is increased in non-neoplastic colonic mucosa from colorectal neoplasia patients

  CRN-pts Mean ΔSCC, SEM (μA·cm− 2) CRN-pts N/n Ctrls Mean ΔSCC, SEM (μA·cm− 2) Ctrls N/n p-value
Baseline SCC 91 ± 10.1 22/42 95 ± 26.6 21/30 0.518
Amiloride −77 ± 13.4 17/38 −30 ± 15.1 13/22 0.006 *
Theophylline 73.5 ± 7.1 17/38 50.5 ± 6.9 13/22 0.025 *
SC-560 + Celecoxib −66.7 ± 3.5 17/38 −54.7 ± 4.3 13/22 0.036 *
PGE2 87.5 ± 32.3 15/26 73.0 ± 17.3 10/19 0.275
Bumetanide −41.5 ± 5.3 15/32 −55.0 ± 9.4 7/18 0.261
Ouabain −70.5 ± 14.4 13/24 −93.0 ± 14.7 7/18 0.431
  1. Baseline SCCs are absolute values, while amiloride (20 μM, apical), theophylline (400 μM, both sides), SC-560 + Celecoxib (500 μM, both sides), prostaglandin (PGE2) (100 nM, serosal), bumetanide (13 μM, serosal) and ouabain (200 μM, serosal) effects are changes from prestimulatory SCC (ΔSCC). SC-560 and Celecoxib are selective COX-1 and COX-2 inhibitors. SC-560 + Celecoxib represent the combined SCC inhibition data of both COX-1/indomethacin and COX-2/indomethacin application. CRN-pts values represent SCC or ΔSCC in biopsies from colorectal neoplasia patients and ctrls values are for patients without colorectal neoplasia. N = number of patients, n = number of biopsies, in parenthesis (N/n). * p-value < 0.05